Plain-English translation of NCT07019922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called elsunersen in children who have a rare genetic seizure disorder caused by a change in the SCN2A gene. The seizures in this condition typically start before a baby is 3 months old and happen very frequently. Researchers want to see if this medication can safely help reduce how often these seizures occur.
Children with this genetic form of epilepsy have very few treatment options, and the seizures are often difficult to control with standard medications. This trial exists to find out whether this new treatment can help these children by targeting the specific genetic cause of their seizures.
You likely qualify if…
You likely don't qualify if…
Your child would receive the new medication during an open-label treatment period, meaning you and the doctors know what medication is being given (unlike a blinded trial where it's kept secret). The trial involves 40 children across multiple medical centers and will track your child's seizure frequency and overall safety. You would attend regular visits where the research team monitors how your child is responding to the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States